Backs FY26 adjusted EBITDA view $20.5M-$25M. “Concurrently, we continue to optimize our organization through cost reductions, improved efficiencies, and elevated quality. I am energized by our achievements during the quarter and remain highly optimistic and committed to building on this momentum throughout the year,” stated Paul Josephs, President and Chief Executive Officer of Lifecore (LFCR).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Analyst Reiterates Buy on Lifecore Despite Weak Q1, Citing Confidence in 2026 Targets and Attractive Risk-Reward
- Lifecore price target raised to $6 from $5.50 at Barrington
- Lifecore management to meet with Barrington
- Is LFCR a Buy, Before Earnings?
- Lifecore Biomedical Earnings Call Signals Profitable Shift